TScan Therapeutics Inc TCRX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EDT
7.38UNCH (UNCH)
Volume
2,353
Close
7.38quote price arrow up+0.12 (+1.65%)
Volume
88,393
52 week range
1.62 - 9.00
Loading...
  • Open7.28
  • Day High7.51
  • Day Low7.11
  • Prev Close7.26
  • 52 Week High9.00
  • 52 Week High Date03/27/24
  • 52 Week Low1.62
  • 52 Week Low Date05/01/23

Key Stats

  • Market Cap371.23M
  • Shares Out50.30M
  • 10 Day Average Volume0.32M
  • Dividend-
  • Dividend Yield-
  • Beta0.9
  • YTD % Change26.59

KEY STATS

  • Open7.28
  • Day High7.51
  • Day Low7.11
  • Prev Close7.26
  • 52 Week High9.00
  • 52 Week High Date03/27/24
  • 52 Week Low1.62
  • 52 Week Low Date05/01/23
  • Market Cap371.23M
  • Shares Out50.30M
  • 10 Day Average Volume0.32M
  • Dividend-
  • Dividend Yield-
  • Beta0.9
  • YTD % Change26.59

RATIOS/PROFITABILITY

  • EPS (TTM)-2.49
  • P/E (TTM)-2.96
  • Fwd P/E (NTM)-7.08
  • EBITDA (TTM)-88.097M
  • ROE (TTM)-71.29%
  • Revenue (TTM)21.049M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-423.86%
  • Debt To Equity (MRQ)19.92%

EVENTS

  • Earnings Date05/09/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On TScan Therapeutics Inc

 

Profile

MORE
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The...
Timothy Barberich
Non-Executive Independent Chairman
Gavin Macbeath Ph.D.
Chief Executive Officer
Jason Amello
Principal Financial Officer, Principal Accounting Officer, Treasurer
Justin McCue Ph.D.
Chief Technology Officer
Leiden Dworak CPA
Vice President - Finance
Address
880 Winter Street
Waltham, MA
02451
United States

Top Peers

SYMBOLLASTCHG%CHG
MGTX
MeiraGTx Holdings PLC
4.86-0.07-1.42%
PGEN
Precigen Inc
1.42+0.02+1.43%
HOWL
Werewolf Therapeutics Inc
6.39-0.05-0.78%
OCGN
Ocugen Inc
1.18-0.07-5.60%
CRBU
Caribou Biosciences Inc
3.85-0.13-3.27%